[go: up one dir, main page]

MX2014000522A - Composicion y metodo para tratar virus del papiloma humano (vph). - Google Patents

Composicion y metodo para tratar virus del papiloma humano (vph).

Info

Publication number
MX2014000522A
MX2014000522A MX2014000522A MX2014000522A MX2014000522A MX 2014000522 A MX2014000522 A MX 2014000522A MX 2014000522 A MX2014000522 A MX 2014000522A MX 2014000522 A MX2014000522 A MX 2014000522A MX 2014000522 A MX2014000522 A MX 2014000522A
Authority
MX
Mexico
Prior art keywords
compositions
hpv
relates
composition
present
Prior art date
Application number
MX2014000522A
Other languages
English (en)
Inventor
Brigitte Evrard
Marie Piette
Isabelle Coïa
Original Assignee
Univ Bruxelles
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45877205&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014000522(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Bruxelles filed Critical Univ Bruxelles
Publication of MX2014000522A publication Critical patent/MX2014000522A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a composiciones liofilizadas que comprenden cidofovir, hidroxipropilmetilcelulosa (HPMC) o hidroexietilcelulosa (HEC) y opcionalmente un plastificante. En particular, la presente invención se refiere a tales composiciones que forman una matriz sólida porosa en forma de hoja. La invención también se refiere a métodos para producir tales composiciones. La invención se refiere además a tales composiciones para utilizar en el tratamiento de infecciones por virus del papiloma humano (HPV) y malignidades asociadas con HPV, en particular lesiones por HPV y cáncer cervical.
MX2014000522A 2011-07-15 2012-07-13 Composicion y metodo para tratar virus del papiloma humano (vph). MX2014000522A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161508473P 2011-07-15 2011-07-15
EP11174193 2011-07-15
PCT/EP2012/063796 WO2013010942A1 (en) 2011-07-15 2012-07-13 Composition and method for treating hpv

Publications (1)

Publication Number Publication Date
MX2014000522A true MX2014000522A (es) 2014-05-30

Family

ID=45877205

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014000522A MX2014000522A (es) 2011-07-15 2012-07-13 Composicion y metodo para tratar virus del papiloma humano (vph).

Country Status (12)

Country Link
US (1) US9211338B2 (es)
EP (1) EP2731588B1 (es)
JP (1) JP2014520834A (es)
KR (1) KR20140054067A (es)
CN (1) CN103889400A (es)
AU (1) AU2012285969A1 (es)
BR (1) BR112014000877A2 (es)
CA (1) CA2841851A1 (es)
CL (1) CL2014000110A1 (es)
EA (1) EA201490220A1 (es)
MX (1) MX2014000522A (es)
WO (1) WO2013010942A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013010942A1 (en) 2011-07-15 2013-01-24 Femalon S.A. Composition and method for treating hpv
US20200253994A1 (en) * 2019-02-11 2020-08-13 Chemistryrx Pyrimidine derivative containing compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020039594A1 (en) * 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
US8178123B2 (en) * 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
US8907153B2 (en) * 2004-06-07 2014-12-09 Nuvo Research Inc. Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same
CN1698643A (zh) * 2005-05-27 2005-11-23 山东恒瑞医药科技发展有限公司 西多福韦脂质体及其制备方法
WO2007035515A2 (en) * 2005-09-15 2007-03-29 Umd, Inc. A method of intraepithelial and systemic exposure of therapeutic agents following vaginal and oral cavity administration
EP1837020A1 (en) 2006-03-24 2007-09-26 Bioalliance Pharma Mucosal bioadhesive slow release carrier for delivering active principles
WO2013010942A1 (en) 2011-07-15 2013-01-24 Femalon S.A. Composition and method for treating hpv

Also Published As

Publication number Publication date
KR20140054067A (ko) 2014-05-08
BR112014000877A2 (pt) 2017-02-21
NZ620042A (en) 2015-09-25
US20140170219A1 (en) 2014-06-19
CN103889400A (zh) 2014-06-25
CL2014000110A1 (es) 2014-10-24
WO2013010942A1 (en) 2013-01-24
CA2841851A1 (en) 2013-01-24
EA201490220A1 (ru) 2014-07-30
AU2012285969A1 (en) 2014-01-30
JP2014520834A (ja) 2014-08-25
US9211338B2 (en) 2015-12-15
EP2731588B1 (en) 2016-04-06
EP2731588A1 (en) 2014-05-21

Similar Documents

Publication Publication Date Title
MX2012002942A (es) Metodo para la preparacion de una forma cristalina de 1-cloro-4-(beta-d-glucopiranos-1-il)-2-(4-((s)-teteahidrofuran-3- iloxi)bencil)-benceno.
MX2018002301A (es) Composiciones de glucano y usos de las mismas.
MX340830B (es) Vacuna neumococica y usos de la misma.
MX2012005782A (es) Procedimientos, composiciones y kits de liofilizacion.
CO6480995A2 (es) Construcciones novedosas de proteina del virus de pailoma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv
TW200716646A (en) (S)-N-methylnaltrexone
MX2012000396A (es) Metodos y composiciones para uso en tartamientos celulares.
MX361413B (es) Formas cristalinas de un macrólido y usos para las mismas.
CL2012003075A1 (es) Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion.
ZA200904932B (en) Papillomavirus E2 polypeptide used for vaccination
MY161601A (en) Films and compositions comprising the same
MX2013014033A (es) Composicion descongelante.
MD4444B1 (ro) Compoziţie de dejivrare şi utilizarea ei
EP4406549A3 (en) Human-derived anti-huntingtin (htt) antibodies and uses thereof
BRPI0810951A2 (pt) Proteína l1 hpv6, polinucleotídeo, vetor, célula, composição, partícula semelhante ao vírus (vlp) hpv6, método para produzir uma proteína l1 do hpv, vacina para prevenção de condiloma acuminado ou de infecções porhpv, uso da proteína, método para prevenção de condiloma acuminado ou infecções por hpv, método pra obter uma vlp de uma proteína l1 do hpv6 e método para produzir uma vacina para a prevenção de condiloma acuminado ou de infecções por hpv
MX2015005881A (es) Compuestos de junta premezclada que usan carboximetilcelulosa no uniformemente sustituida.
MX2018013340A (es) Combinaciones de vacunas terapeuticas para el vph.
WO2014197835A3 (en) Methods and compositions for the treatment of cancer
PH12015502589A1 (en) 4`-azido, 3`-deoxy-3`-fluoro substituted nucleoside derivatives
MX2012001691A (es) Composiciones de linaclotida que se desintegran oralmente.
JP2010536929A5 (es)
PT2222335T (pt) Composições imunogénicas e de vacina do vírus da língua azul, métodos de utilização e métodos de produção das mesmas
MX2014000522A (es) Composicion y metodo para tratar virus del papiloma humano (vph).
MX360449B (es) Vacunas para el virus del papiloma humano y metodos para su uso.
MX367327B (es) Formulaciones, sales y polimorfos de transnorsertralina y usos de los mismos.